<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641212</url>
  </required_header>
  <id_info>
    <org_study_id>SD-005-0414</org_study_id>
    <secondary_id>D5360C00414</secondary_id>
    <nct_id>NCT00641212</nct_id>
  </id_info>
  <brief_title>Children, Perennial Allergic Rhinitis (PAR), l-t Growth</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on
      growth in children with perennial allergic rhinitis over 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in height over a 12 month period</measure>
    <time_frame>3 monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in growth velocity over a 12 month period.</measure>
    <time_frame>3 monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other safety - assessed by adverse event query</measure>
    <time_frame>3 monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">209</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Rhinocort AQUA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator, is a candidate for treatment with nasal steroids
             based on a history of either a) inadequate control of symptoms with antihistamines,
             decongestants and/or immunotherapy, or b) prior successful treatment with nasal
             steroids.

          -  A documented history of at least one year of perennial allergic rhinitis.

          -  A positive response to a skin prick test for perennial allergens that must be present
             in the subject's environment.

          -  Height and weight within normal limits.

        Exclusion Criteria:

          -  Any disease which may affect growth

          -  Sexual development later than Tanner stage I.

          -  Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza,
             upper respiratory tract infection or structural abnormalities of the nose (e.g.,
             septal deviation, nasal polyps) symptomatic enough to cause significant nasal
             obstruction as judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertil Andersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Perennial allergic rhinitis</keyword>
  <keyword>Paediatric</keyword>
  <keyword>Growth</keyword>
  <keyword>budesonide</keyword>
  <keyword>Rhinocort AQUA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

